Table 3.
Evaluation of compounds 6 and 7 against a broad range of DNA- and RNA-viruses 1.
| Compound | CC50 2 (µM) | Antiviral EC50 3 (µM) - cell line 4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HEL | HeLa | Vero | HEL | HeLa | Vero | ||||||
| HSV-1 | HSV-2 | HSV-1/TK- | Vaccinia Virus | Human Coronavirus 229E | RSV | Yellow Fever Virus | Zika Virus | ||||
| 6 | >100 | >100 | >100 | 20 | 7.8 | 7.4 | 7.2 | 11 | 7.7 | >100 | >100 |
| 7 | >100 | >100 | >100 | 43 | 6.5 | 11 | 32 | 32 | 60 | 55 | 14 |
| Cidofovir | >250 | >250 | >250 | 2.4 | 1.0 | 5.8 | 37 | - | - | - | - |
| Aciclovir | >250 | >250 | >250 | 2.4 | 0.05 | 146 | >250 | - | - | - | - |
| Ganciclovir | >100 | >100 | >100 | 0.1 | 0.03 | 8.9 | >100 | - | - | - | - |
| UDA 5 | >100 | >100 | >100 | - | - | - | - | 1.8 | - | - | - |
| Ribavirin | >250 | >250 | >250 | - | - | - | - | - | 5.0 | 119 | - |
| Mycophenolic acid | >100 | >100 | >100 | - | - | - | - | - | - | 0.7 | 0.8 |
1 Viruses: herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2); a thymidine-kinase deficient (TK-) mutant of HSV-1; vaccinia virus; human coronavirus 229E; respiratory syncytial virus (RSV); yellow fever virus and Zika virus. 2 50% Cytotoxic concentration, assessed in mock-infected cells by the MTS cell viability assay. 3 50% Effective concentration offering 50% protection against virus-induced CPE, as determined by the MTS assay. 4 Cell lines: HEL, human embryonic lung fibroblast cells; HeLa, human cervix carcinoma cells; Vero, African Green monkey kidney cells. 5 UDA: Urtica dioica agglutinin lectin; for this compound, concentrations are expressed in µg/mL.